Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Clin Pediatr (Phila) ; 46(4): 320-4, 2007 May.
Artigo em Inglês | MEDLINE | ID: mdl-17475989

RESUMO

There has been considerable publicity about the lack of benefit and potential dangers of syrup of ipecac. In November 2003, the American Academy of Pediatrics recommended against its use. Pharmacies in Houston, Texas were surveyed by telephone before (survey 1) and after (survey 2) the American Academy of Pediatrics' recommendation to determine whether ipecac availability changed. There were 126 pharmacies interviewed at survey 1, and 128 interviewed at survey 2. Pharmacies in survey 1 were more likely than those in survey 2 to sell ipecac (79% versus 64%, P < .01) and to have it in stock (75% versus 48%, P < .001). Pharmacies mostly stored ipecac on the shelves (67%, survey 1; 59%, survey 2, P = .27). Although syrup of ipecac availability has declined significantly, it is still available in more than 50% of pharmacies. Health care providers should advise against its use and advocate that pharmacies remove it.


Assuntos
Eméticos/provisão & distribuição , Ipeca/provisão & distribuição , Intoxicação/terapia , Academias e Institutos , Uso de Medicamentos/tendências , Eméticos/administração & dosagem , Acessibilidade aos Serviços de Saúde , Humanos , Ipeca/administração & dosagem , Farmácias , Texas/epidemiologia , Fatores de Tempo , População Urbana
2.
J Toxicol Clin Toxicol ; 41(3): 217-21, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12807301

RESUMO

INTRODUCTION: The home administration of ipecac syrup remains a recommendation in some guidelines for the management of specific pediatric poisonings. A common challenge for poison specialists is how to approach the situation when ipecac syrup is indicated but not kept in the home. This study examines whether or not ipecac syrup can be administered and produce timely emesis in this situation. METHODS: Over a 6-month period, a prospective observational study was undertaken to determine if ipecac syrup can be administered in a timely manner when it is indicated but not available in the home. Cases where ipecac syrup was indicated but not kept in the home were included if parents stated that they could obtain ipecac within 15 minutes. Timely administration and the onset of emesis were defined as < 30 min and < 60 min, respectively. RESULTS: During our study 14,603 human exposures were evaluated; ipecac syrup was recommended by a poison specialist in 75 cases, and 25 of these were included in our study. Ages ranged from 1 to 6 years. The mean time to administration of ipecac from exposure time was 40 min (SD +/- 14 min). Administration of ipecac syrup occurred in < 30 min in 20% of the cases. The mean time to first emesis from exposure was 58 min (SD +/- 13). Initial emesis occurred in < 60 min in 36% of the cases. CONCLUSIONS: Ipecac syrup was rarely recommended by our center and was frequently unavailable when it was recommended. Ipecac syrup often could not be administered in a timely manner because it was not kept in the home. Parents of pediatric patients who have a significant ingestion should not be referred to purchase ipecac syrup.


Assuntos
Eméticos/administração & dosagem , Ipeca/administração & dosagem , Telemedicina , Criança , Pré-Escolar , Eméticos/provisão & distribuição , Assistência Domiciliar , Humanos , Lactente , Ipeca/provisão & distribuição , Cooperação do Paciente , Intoxicação/tratamento farmacológico , Estudos Prospectivos , Fatores de Tempo
3.
N Z Med J ; 111(1076): 402-4, 1998 Oct 23.
Artigo em Inglês | MEDLINE | ID: mdl-9830429

RESUMO

Syrup of ipecacuanha has previously been used to decontaminate patients following toxic or potentially toxic ingestions. The recent removal of this product from distribution in New Zealand has caused some concern to health professionals. This article outlines the relative merits of syrup of ipecacuanha and activated charcoal, and concludes that the latter is preferable in many respects. Details of its appropriate administration are discussed.


Assuntos
Antídotos/uso terapêutico , Carvão Vegetal/uso terapêutico , Eméticos/uso terapêutico , Ipeca/uso terapêutico , Intoxicação/tratamento farmacológico , Eméticos/provisão & distribuição , Humanos , Ipeca/provisão & distribuição , Nova Zelândia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA